A Role for Timp3 in Microbiota-Driven Hepatic Steatosis and Metabolic Dysfunction
Maria Mavilio(University of Rome Tor Vergata), Massimo Federici(University of Rome Tor Vergata), Loredana Fiorentino(University of Rome Tor Vergata), Viviana Casagrande(University of Rome Tor Vergata), Rémy Burcelin(Inserm), Céline Garret(Université Toulouse III - Paul Sabatier), Rossella Menghini(University of Rome Tor Vergata), Marta Fabrizi(University of Rome Tor Vergata), Alessandro Mauriello(University of Rome Tor Vergata), Alessio Farcomeni(Department of Public Health), Giovanni Monteleone(University of Rome Tor Vergata), Valentina Marchetti(Scripps Research Institute), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), Arianna Marino(University of Rome Tor Vergata), Ben A. Kappel(University of Rome Tor Vergata), Marina Cardellini(University of Rome Tor Vergata), Ivan Monteleone(University of Rome Tor Vergata)
Cited by 8
Related Papers
Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug
|Nature Medicine|2017|1.6k
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
|European Heart Journal|2023|1.4k
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|660